Association between the -1562 C/T MMP-9 polymorphism and cerebrovascular disease in a Polish population

Neurologia i Neurochirurgia Polska

Volumn 44, Issue 4, 2010, Pages 350-357

  Szczudlik, Piotr ^a   Borratyńska, Anna ^b  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

1562 C T polymorphism of MMP 9 gene; Cerebrovascular disease; Matrix metalloproteinase 9

Indexed keywords

GELATINASE B;

AGED; ARTERIOSCLEROSIS; BRAIN ISCHEMIA; CAROTID ARTERY DISEASE; CEREBROVASCULAR DISORDERS; COMPARATIVE STUDY; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HUMAN; MALE; MIDDLE AGED; POLAND; PREDICTIVE VALUE; RISK ASSESSMENT; RISK FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ARTERIOSCLEROSIS; BRAIN ISCHEMIA; CAROTID ARTERY DISEASES; CEREBROVASCULAR DISORDERS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; POLAND; POLYMORPHISM, GENETIC; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; RISK FACTORS;

EID: 77956892642     PISSN: 00283843     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0028-3843(14)60294-2     Document Type: Article

References (31)

1. Nagase H., Woessner J.F. Matrix metalloproteinases. JBC 1999; 274: 21491-21494.
2. Ye S. Polymorphism in matrix metalloproteinase gene prom oters: implication in regulation of gene expression and susceptibility of various diseases. Matrix Biology 2000; 19: 623-629.
3. Zhang B., Ye S., Herrmann SM., et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999; 99: 1788-1794. (Pubitemid 29181405)
4. Kaplan R.C., Smith N.L., Zucker S., et al. Matrix metalloproteinase-3 (MMP3) and MMP9 genes and risk of myocardial infarction, ischemic stroke, and hemorrhagic stroke. Atherosclerosis 2008; 201: 130-137.
5. Fornage M., Mosley T.H., Jack C.R., et al. Family-based association study of matrix metalloproteinase-3 and -9 haplotypes with susceptibility to ischemic white matter injury. Hum Genet 2007; 120: 671-680. (Pubitemid 44942851)
6. Yasmin C.M., McEniery K.M., Oshaughnessy P.H., et al. Variation in the human matrix metalloproteinase-9 gene is associa - ted with arterial stiffness in healthy individuals. Arterioscler Thromb Vasc Biol 2006; 26: 1799-1805. (Pubitemid 44305333)
7. Ye S. Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res 2006; 69: 636-645. (Pubitemid 43139726)
8. Lijnen R.H. Metalloproteinases in development and progression of vascular disease. Pathophysiol Haemost Thromb 2003/2004; 33: 275-281. (Pubitemid 40278695)
9. Galis Z.S., Sukhova G.K., Lark M.W., et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest 1994; 94: 2493-2503.
10. Kim S.C., Sngh M., Huang J., et al. Matrix metalloproteinase-9 in cerebral aneurysms. Neurosurgery 1997; 4: 642-647.
11. Montaner J., Alvarez-Sabin J., Molina C.A., et al. Matrix metalloproteinase expression after human cardioembolic stroke. Stroke 2001; 32: 1759-1766.
12. Montaner J., Alvarez-Sabin J., Molina C.A., et al. Matrix metalloproteinase expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 2001; 32: 2762-2767. (Pubitemid 33134461)
13. Costelannos M., Leira R., Serena J., et al. Plasma metalloproteinase- 9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 2003; 34: 40-46. (Pubitemid 36070797)
14. Abilleira S., Montaner J., Molina C.A., et al. Matrix metalloproteinase- 9 concentration after spontaneous intracerebral hemorrhage. J Neurosurg 2003; 99: 65-70. (Pubitemid 36753878)
15. Zhang B., Dhillon S., Geary I., et al. Polymorphism in matrix metalloproteinase-1,-3,-9,-12 genes in relation to subarachnoid hemorrhage. Stroke 2001; 32: 2198-2202. (Pubitemid 32868122)
16. Pannu H., Kim D.H., Guo D., et al. The role of MMP-2 and MMP-9 polymorphisms in sporadic intracranial aneurysms. J Neurosurg 2006; 105: 418-423. (Pubitemid 44358753)
17. Adams H.P, Bendixen B.H, Kappelle L.J., et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993; 24: 35-41.
18. Alberti K.G, Zimmet P.Z. Definition, diagnosis and classification of diabetes mellitus provisional proposal of WHO consultation. Diabet Med 1998; 15: 539-553.
19. Jones C.B., Sane D.C., Herrington D.M. Matrix metalloproteinases: a review of their structure and role in acute coronary syndrome. Cardiovasc Res 2003; 59: 812-823.
20. Loftus I.M., Naylor R.A., Goodall S., et al. Increased matrix metalloproteinase-9 activity in unstable carotid plaques. Stroke 2000; 31: 40-47.
21. Loftus I.M., Naylor R.A., Bell P.R., et al. Plasma MMP-9 a marker of carotid plaque instability. Eur J Vasc Surg 2001; 21: 17-21.
22. Montaner J., Fernandez-Cadenas I., Molina C.A., et al. Safety profile of tissue plasminogen activator treatment among stroke patients carrying a common polymorphism (C-1562T) in the promoter region of the matrix metalloproteinase-9 gene. Stroke 2003; 34: 2851-2855. (Pubitemid 37517755)
23. Lee J.M., Yin K., Hsin I., et al. Matrix metalloproteinase-9 and spontaneous hemorrhage in an animal model of cerebral amyloid angiopathy. Ann Neurol 2003; 54: 379-382. (Pubitemid 37072041)
24. Rosenberg G.A., Estrada E.Y., Dencoff J.E. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 1998; 29: 2189-2195.
25. Wang J., Tsirka S.E. Neuroprotection by inhibition of matrix metalloproteinases in a mouse model of intracerebral haemorrhage. Brain 2005; 128: 1622-1633. (Pubitemid 41373681)
26. Rosenberg G., Navratil M. Metalloproteinase inhibition blocks edema in intracerebral hemorrhage in the rat. Neurology 1997; 48: 921-926. (Pubitemid 27175616)
27. Alvarez-Sabin J., Delgado P., Abilleira S., et al. Temporal profile of matrix metalloproteinases and their inhibitors after spontaneous intracerebral hemorrhage. Stroke 2004; 35: 1316-1322.
28. Demestre M., Parkin-Smith G., Petzold A., et al. The pro and the active form of matrix metalloproteinase-9 is increased in serum of patients with amyotrophic lateral sclerosis. J Neuroimmunol 2005; 159: 146-154. (Pubitemid 40136512)
29. Beuche W., Yushchenko M., Mäder M., et al. Matrix metalloproteinase- 9 is elevated in serum of patients with amyotrophic lateral sclerosis. Neuroreport 2000; 11: 3419-3422.
30. Szolnoki Z., Somogyvári F., Kondacs A., et al. Evaluation of the modifying effects of unfavourable genotypes on classical clinical risk factors for ischaemic stroke. J Neurol Neurosurg Psychiatry 2003; 74: 1615-1620. (Pubitemid 37542048)
31. Hop J.W., Rinkel G.J., Algra A., et al. Case-fatality rates and functional outcome after subarachnoid hemorrhage: a system atic review. Stroke 1997; 28: 660-664. (Pubitemid 27118394)